Phase I Study of Milatuzumab for Graft Versus Host Disease

Clinical trial NCT01663766 · TERMINATED

Trial details

NCT number: NCT01663766
Sponsor: Gilead Sciences
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

GVHD (Acute or Chronic)Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Myelodysplastic Syndrome Chronic Myelogenous Leukemia (CML)Multiple Myeloma (MM)Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)

Start date: 2013-12-01
Primary completion: 2015-03-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.